APTEVO THERAPEUTICS INC (APVO) Earnings History & Surprises

NASDAQ:APVO • US03835L7029

6.73 USD
+0.07 (+1.05%)
At close: Mar 4, 2026
6.36 USD
-0.37 (-5.5%)
After Hours: 3/4/2026, 8:08:42 PM

Past quarterly earnings results for APTEVO THERAPEUTICS INC (APVO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release DateMay 12, 2026
PeriodQ4 / 2025
EPS Estimate-$8.26
Revenue Estimate

Last Reported

Most Recent
Release DateFeb 16, 2026
PeriodQ3 / 2025
EPS Reported-$33.48
EPS Surprise 12.75%
Revenue Surprise %

Beat Rate

Last 8 Quarters
38%
EPS and Revenuebeats vs estimates

Quarterly Earnings Results

EPS & Revenue History (USD)

Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q3 2025 -33.48 -38.37 12.75% 90.57% - -
Q2 2025 -151.20 -1,527.55 90.10% 87.77% - -
Q1 2025 -1,580.40 -1,545.91 -2.23% 78.54% - -
Q4 2024 -1,647.40 -158.10 -942.00% 63.86% - -
Q3 2024 -355.20 -2,532.35 85.97% 97.82% - -
Q2 2024 -1,235.80 -4,943.94 75.00% 96.91% - -
Q1 2024 -7,363.00 -9,695.41 24.06% -157.98% - -
Q4 2023 -4,558.40 -13,616.59 66.52% 85.26% - -
Q3 2023 -16,280.00 -24,908.40 34.64% 66.67% - -
Q2 2023 -40,048.80 -37,196.54 -7.67% -122.04% - -
Q1 2023 12,698.40 -39,355.27 132.27% 125.16% - -100.00%
Q4 2022 -30,932.00 -50,813.14 39.13% 25.20% - -100.00%
Q3 2022 -48,840.00 -54,466.37 10.33% -4.90% - -100.00%
Q2 2022 181,684.80 -44,170.90 511.32% 418.86% 3.494M -100.00% -100.00%
Q1 2022 -50,468.00 -38,192.88 -32.14% 5.49% 3.114M 3.825M -18.59% 28.62%
Q4 2021 -41,351.20 -43,008.50 3.85% 33.85% 3.665M 3.468M 5.68% 54.45%
Q3 2021 -46,560.80 -48,986.52 4.95% 31.90% 3.096M 3.723M -16.84% 111.62%
Q2 2021 -56,980.00 -66,422.40 14.22% 16.67% 3.11M 918K 238.78% 557.51%
Q1 2021 -53,398.40 56,126.93 -195.14% 42.25% 2.421M 13.328M -81.84% -
Q4 2020 -62,515.20 -40,351.61 -54.93% - 2.373M 1.78M 33.31% -
Q3 2020 -68,376.00 -66,920.57 -2.17% - 1.463M 574.943K 154.46% -
Q2 2020 -68,376.00 -68,249.02 -0.19% - 473K 266.903K 77.22% -
Q1 2020 -92,470.40 -78,046.32 -18.48% - 5.272M -100.00% -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

APVO EPS Q2Q GrowthAPVO EPS Q2Q GrowthEPS Q2Q Growth Q1/21 Q3/21 Q1/22 Q3/22 Q1/23 Q3/23 Q1/24 Q3/24 Q1/25 Q3/25 0 100 -100 200 300 400

Revenue Historical Q2Q growth and Acceleration

APVO Revenue Q2Q GrowthAPVO Revenue Q2Q GrowthRevenue Q2Q Growth Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 0 200 400

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
2
Average EPS beat (4)
-210.35%
Max EPS beat (4)
90.10%
Min EPS beat (4)
-942.00%

Revenue beat statistics

Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A

Analysis

In the last 4 quarters, APVO has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, APVO reported -210.3% below the EPS estimates on average.
→ Find peers who consistently beat earnings by at least 10% in the last 4 quarters

APTEVO THERAPEUTICS INC / APVO Earnings FAQ

When did APTEVO THERAPEUTICS INC (APVO) report earnings last quarter?

APTEVO THERAPEUTICS INC (APVO) last reported earnings on 2/16/2026.


Did APTEVO THERAPEUTICS INC (APVO) beat earnings estimates last quarter?

APTEVO THERAPEUTICS INC (APVO) beat EPS estimates and missed revenue estimates in the most recent quarter.


How often does APTEVO THERAPEUTICS INC (APVO) beat earnings estimates?

In the last 4 quarters, APTEVO THERAPEUTICS INC (APVO) has beaten EPS estimates in 2 out of 4 releases.